{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:36:50Z","timestamp":1790105810198,"version":"4.0.1"},"reference-count":8,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.2967\/jnumed.122.265352","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T15:40:15Z","timestamp":1686238815000},"page":"1083-1086","source":"Crossref","is-referenced-by-count":40,"title":["Regression of Myocardial<sup>99m<\/sup>Tc-DPD Uptake After Tafamidis Treatment of Cardiac Transthyretin Amyloidosis"],"prefix":"10.2967","volume":"64","author":[{"given":"Maria","family":"Papathanasiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank M.","family":"Bengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiste-Monika","family":"Jakstaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Varasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Luedike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Carpinteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rischpler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2023063006250737000_64.7.1083.1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"2023063006250737000_64.7.1083.2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging."},{"key":"2023063006250737000_64.7.1083.3","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ehjci\/jeab226","article-title":"Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy","volume":"23","author":"Rettl","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging."},{"key":"2023063006250737000_64.7.1083.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2020.03.020"},{"key":"2023063006250737000_64.7.1083.5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12350-022-02960-3","article-title":"Quantitative 99mTc-DPD-SPECT\/CT assessment of cardiac amyloidosis","volume":"30","author":"Kessler","year":"2023","journal-title":"J Nucl Cardiol."},{"key":"2023063006250737000_64.7.1083.6","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s12350-015-0261-x","article-title":"Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis","volume":"23","author":"Casta\u00f1o","year":"2016","journal-title":"J Nucl Cardiol."},{"key":"2023063006250737000_64.7.1083.7","doi-asserted-by":"crossref","unstructured":"Mussinelli R Garcia-Pavia P Gillmore JD . HELIOS-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis. Eur Heart J Suppl. 2022;24(suppl K):suac121.654.","DOI":"10.1093\/eurheartjsupp\/suac121.654"},{"key":"2023063006250737000_64.7.1083.8","doi-asserted-by":"crossref","unstructured":"Kale P Maurer MS Fontana M . Exploratory analyses from the APOLLO-B, a phase 3 study of patisiran in patients with ATTR amyloidosis with cardiomyopathy. Poster presented at: Heart Failure Society of America (HFSA) Annual Scientific Meeting; September 30\u2013October 3, 2022; Washington, DC.","DOI":"10.1016\/j.cardfail.2022.10.017"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.265352","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T13:26:26Z","timestamp":1688131586000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.265352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":8,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,6,30]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.2967\/jnumed.122.265352"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.265352","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}